Investment Rating - The report assigns a "Buy" rating to the company, with a current price of HKD 23.96 and a fair value of HKD 41.12 [8]. Core Insights - The company has formed a strategic partnership with Shiseido China to enhance its technology-driven skincare offerings, positioning itself as a leading platform for high-end skincare solutions tailored for Asian skin [8]. - The company aims to leverage its three major beauty brands (Meili Tianyuan, Nairui'er, and Siyuanli) to reshape the value landscape of the beauty industry, focusing on a dual beauty and health business model [8]. - The company is expected to maintain strong growth, with projected net profits of RMB 344 million, RMB 458 million, and RMB 600 million for the years 2025 to 2027, respectively [8]. Financial Summary - Revenue projections indicate a growth from RMB 2,145 million in 2023 to RMB 4,913 million in 2027, with growth rates of 31.2%, 19.9%, 16.9%, 33.7%, and 22.2% for the respective years [3][12]. - EBITDA is expected to increase from RMB 623 million in 2023 to RMB 1,170 million in 2027, reflecting a robust growth trajectory [3]. - The company's net profit margin is projected to improve from 10.7% in 2023 to 12.2% in 2027, indicating enhanced profitability [12]. - The report highlights a significant increase in return on equity (ROE), expected to rise from 26.9% in 2023 to 36.4% in 2027 [3][12].

Core Insights - Shiseido China has announced a strategic partnership with Beautiful Garden to integrate advanced research technology with high-end salon services, aiming to provide science-based skincare solutions for Chinese consumers [1] - This collaboration will enhance Shiseido's strategic positioning in the rapidly growing medical and lifestyle beauty markets in China [1] Group 1 - The partnership focuses on the technology-driven skincare brand RQ PYOLOGY, specifically designed for Asian skin, which will launch in the salon sector [1] - RQ PYOLOGY aims to offer clinically proven, technology-driven skincare solutions that support post-medical beauty recovery and daily maintenance, creating a "Shiseido Medical Beauty Cycle" in China [1] - The collaboration marks the extension of RQ PYOLOGY from professional medical settings to high-end lifestyle beauty services, achieving a full integration from professional treatment to daily care [1] Group 2 - The first project from this strategic partnership is the "Light Perception Whitening" high-end whitening care program, set to launch in March 2026 at Beautiful Garden's core stores nationwide [1] - This care program targets sensitive skin and post-medical beauty recovery, offering customized whitening solutions for different skin tones, positioning itself in the high-end technology skincare market [1]

Group 1 - The core viewpoint of the news is that the company is focusing on innovation and brand development in the cosmetics sector, achieving significant revenue growth and maintaining a strong market position [1][2][4] - In Q1 2025, the cosmetics segment generated revenue of 526 million yuan with a gross margin of 61.06%, driven by key brands such as Yilian and Aier Doctor, which achieved revenues of 250 million yuan and 236 million yuan respectively [1] - The company launched 47 new products and obtained 12 new patents in the cosmetics segment during the reporting period, emphasizing a research-driven approach and technological innovation [1][2] Group 2 - The company is committed to a dual-brand strategy focusing on Yilian and Aier Doctor while optimizing the operations of other brands, transitioning from a single beauty business to a "beauty + medical beauty" model [3] - The company plans to enhance its core competitiveness through continuous R&D investment, with a projected R&D expenditure of 199 million yuan in 2024 and approximately 42 million yuan in Q1 2025 [2] - The company is advancing its product lines and brand strategies, including the introduction of innovative products and technologies, such as the membrane collagen technology launched by the Kemi brand [4]